BIOLOGICAL · Unmapped registry intervention
Certolizumab Pegol
Find medicine records ·
Find other trials using this name
Clinical trial
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
NCT00160693
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedOpen Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Certolizumab PegolBIOLOGICAL
Sponsors & collaborators
UCB Pharmalead sponsor
Mapped research locations
DallasTexas, United States1St LouisMissouri, United States1San AntonioTexas, United States1LondonUnited Kingdom1ClevelandOhio, United States1TampaFlorida, United States1BerlinGermany1Washington D.C.District of Columbia, United States1OrlandoFlorida, United States1AustinTexas, United States1CharlestonSouth Carolina, United States1CharlotteNorth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00160693 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.